{
    "nctId": "NCT01005641",
    "briefTitle": "ELBA: Exemestane and Lapatinib in Advanced Breast Cancer",
    "officialTitle": "Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "recommended dose of lapatinib given in combination with standard dose of exemestane in patients with advanced hormone-responsive breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological diagnosis of breast cancer\n* Indication for hormonal therapy (ER and/or PgR positive)\n* Stage IV disease\n* Female gender\n* Postmenopausal status (patients treated with LHRH analogs are eligible for the Phase II part of the study)\n* At least one target or non-target lesion according to RECIST criteria\n* ECOG Performance Status 0-2\n* Adequate bone marrow (neutrophils \\> or = 1.500/mm\u00b3, platelets \\> or = 100.000/mm\u00b3 and hemoglobin \\> or = 9 g/dl), hepatic (GOT, GPT \\< 2.5 e bilirubin \\<1.25 times the value of upper normal limit) and renal (creatinine \\< 1.25 times the value of upper normal limit) function\n* Adequate cardiac function (FEVS \\> or = 50%)\n* Able to take oral medications\n* Life expectancy \\> 3 months\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any previous hormone therapy for metastatic disease\n* More than one line of chemotherapy for metastatic disease (first line chemotherapy is permitted)\n* Symptomatic cerebral metastases\n* Planned concomitant radiation therapy in the first month of therapy (for those patients participating in the dose finding phase of the study)\n* Previous therapy with exemestane, including as adjuvant therapy (previous therapy with non-steroidal aromatase inhibitors is permitted)\n* Previous or concurrent malignancy in past 5 years (excluding adequately treated basal cel or spinocellular skin cancer and in situ carcinoma of the cervix)\n* Treatment with experimental pharmacologic therapy within 4 weeks of enrollment in the study\n* Unable or unwilling to provide signed informed consent\n* Any concurrent illness that would, in the Investigator's opinion, contraindicate the use of the study drugs.\n* Active infection\n* Assumption of CYP3A4 inhibitors or inducers (ketoconazole, itraconazole, fluconazole, macrolide antibiotics, antidepressives, calcium-antagonists, cimetidine, carbamazepine, phenytoin, barbiturates, rifampicin e glucocorticoids)\n* Pregnancy or lactation\n* Unable to comply with follow-up\n* Active hepatobiliary disease (with the exception of Gilbert's syndrome, asymptomatic biliary calculi, hepatic metastases or stabile chronic hepatopathy)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}